

Indian Pharmaceutical Forum, Mumbai, 27 February 2019

Presented by Maria Filancia Scientific Administrator Manufacturing Quality and Supply Chain Integrity European Medicines Agency



- In 2017 the EU was India's 1<sup>st</sup> trading partner while India was the EU's 9<sup>th</sup> largest trading partner.
- Around 30% of the active pharmaceuticals ingredients sold in the EU come from India.
- 75% of India's total demand for medical devices is currently met by imports with nearly 30% of it being supplied by the EU.
- India is leading exporter of generic medicines to the developed world including EU and to the US.

Common goal: ensure protection of public and animal health.



- 1994: <u>Cooperation Agreement between the European Community and the Republic of India on partnership and development Declaration of the Community concerning tariff adjustments Declarations of the Community and India.</u>
- 2005/2006: EU-India Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices.
- 2018: <u>Joint communication to the European parliament and the council: elements for an EU strategy on India.</u>

Mutual interest in reinforcing the dialogue, cooperation, transparency and conformity to international standards and practices in pharmaceuticals and biotechnology.



#### COOPERATION

- learn from each other
- avoid duplications
- expand the supervision of products and companies



#### **HARMONISATION**

 standardised good manufacturing principles

**TRUST** 

CULTURE OF QUALITY

# Thank you.

### Further information

maria.filancia@ema.europa.eu

#### **European Medicines Agency**

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

Follow us on **9 @EMA\_News**